Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

Show other versions (1)

Background and objective: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, ca...

Full description

Bibliographic Details
Main Authors: E. Caronna, V. José Gallardo, A. Alpuente, M. Torres-Ferrus, N.M. Sánchez-Mateo, J. Viguera-Romero, A.C. López-Veloso, A. López-Bravo, A.B. Gago-Veiga, P. Irimia Sieira, J. Porta-Etessam, S. Santos-Lasaosa, P. Pozo-Rosich
Format: Article
Language:Spanish
Published: Elsevier España 2021-10-01
Series:Neurología
Subjects:
Migraña
CGRP
COVID-19
Anticuerpos monoclonales
SARS-CoV-2
Online Access:http://www.sciencedirect.com/science/article/pii/S0213485321000566

Internet

http://www.sciencedirect.com/science/article/pii/S0213485321000566

Similar Items